Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research
Bruker (Nasdaq: BRKR) has launched the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope designed for pharmaceutical and life science research. The device features a patented coherence reduction method for artifact-free infrared laser imaging in both transmission and reflection modes.
The microscope offers ultrafast IR imaging capabilities over large areas with enhanced spatial resolution. Key features include a large field of view, complete automation, and the ability to rapidly determine chemical complexity in biological tissues. The system integrates with Bruker's MALDI Imaging methods for multimodal tissue characterization and includes AI-powered data evaluation.
According to Dr. Guillaume Mabilleau from Centre Hospitalier Universitaire Angers, the microscope's speed and QCL technology represent a significant advancement for clinical research, particularly in bone disease diagnosis and treatment. The system also supports pharmaceutical tablet inspection and particle identification with automated sampling, and includes a Python interface for customization.
Bruker (Nasdaq: BRKR) ha lanciato il LUMOS™ II ILIM, un microscopio a imaging infrarosso basato su laser a cascata quantistica (QCL) progettato per la ricerca farmaceutica e nelle scienze della vita. Il dispositivo presenta un metodo brevettato di riduzione della coerenza per immagini infrarosse laser senza artefatti sia in modalità trasmissione che riflessione.
Il microscopio offre capacità di imaging IR ultraveloci su ampie aree con una risoluzione spaziale migliorata. Tra le caratteristiche principali ci sono un ampio campo visivo, automazione completa e la possibilità di determinare rapidamente la complessità chimica nei tessuti biologici. Il sistema si integra con i metodi di Imaging MALDI di Bruker per la caratterizzazione multimodale dei tessuti e include una valutazione dei dati supportata da intelligenza artificiale.
Secondo il Dr. Guillaume Mabilleau del Centre Hospitalier Universitaire Angers, la velocità del microscopio e la tecnologia QCL rappresentano un avanzamento significativo per la ricerca clinica, in particolare nella diagnosi e nel trattamento delle malattie ossee. Il sistema supporta anche l'ispezione di compresse farmaceutiche e l'identificazione di particelle con campionamento automatizzato, e include un'interfaccia Python per la personalizzazione.
Bruker (Nasdaq: BRKR) ha lanzado el LUMOS™ II ILIM, un microscopio de imagen infrarroja basado en láser de cascada cuántica (QCL) diseñado para la investigación farmacéutica y en ciencias de la vida. El dispositivo cuenta con un método patentado de reducción de coherencia para imágenes de láser infrarrojo sin artefactos tanto en modos de transmisión como de reflexión.
El microscopio ofrece capacidades de imagen IR ultrarrápidas sobre grandes áreas con una resolución espacial mejorada. Las características clave incluyen un amplio campo de visión, automatización completa y la capacidad de determinar rápidamente la complejidad química en tejidos biológicos. El sistema se integra con los métodos de Imaging MALDI de Bruker para la caracterización multimodal de tejidos e incluye evaluación de datos impulsada por inteligencia artificial.
Según el Dr. Guillaume Mabilleau del Centre Hospitalier Universitaire Angers, la velocidad del microscopio y la tecnología QCL representan un avance significativo para la investigación clínica, especialmente en el diagnóstico y tratamiento de enfermedades óseas. El sistema también admite inspección de tabletas farmacéuticas e identificación de partículas con muestreo automatizado, y cuenta con una interfaz de Python para personalización.
Bruker (Nasdaq: BRKR)는 제약 및 생명과학 연구를 위해 설계된 LUMOS™ II ILIM이라는 양자 캐스케이드 레이저(QCL) 기반의 적외선 이미징 현미경을 출시했습니다. 이 장치는 전송 및 반사 모드 모두에서 아티팩트 없는 적외선 레이저 이미징을 위한 특허 받은 코히어런스 저감 방법을 특징으로 합니다.
이 현미경은 향상된 공간 해상도로 넓은 영역에서 초고속 IR 이미징 기능을 제공합니다. 주요 기능으로는 넓은 시야, 완전한 자동화, 생물학적 조직에서 화학적 복잡성을 신속하게 결정할 수 있는 기능이 포함됩니다. 이 시스템은 Bruker의 MALDI 이미징 방법과 통합되어 다중 모드 조직 특성화를 수행하며 AI 기반 데이터 평가를 포함합니다.
Centre Hospitalier Universitaire Angers의 Guillaume Mabilleau 박사에 따르면, 이 현미경의 속도와 QCL 기술은 임상 연구, 특히 뼈 질환 진단 및 치료에 있어 중요한 발전을 나타냅니다. 이 시스템은 제약 정제 검사와 자동 샘플링을 통한 입자 식별을 지원하며, 사용자 맞춤형 개발을 위한 Python 인터페이스를 포함합니다.
Bruker (Nasdaq: BRKR) a lancé le LUMOS™ II ILIM, un microscope à imagerie infrarouge basé sur un laser à cascade quantique (QCL) conçu pour la recherche pharmaceutique et en sciences de la vie. L'appareil dispose d'une méthode brevetée de réduction de cohérence pour une imagerie laser infrarouge sans artefacts, à la fois en mode transmission et réflexion.
Le microscope offre des capacités d'imagerie IR ultrarapides sur de grandes surfaces avec une résolution spatiale améliorée. Parmi ses caractéristiques principales, on trouve un grand champ de vision, une automatisation complète et la capacité de déterminer rapidement la complexité chimique dans les tissus biologiques. Le système s'intègre avec les méthodes d'imagerie MALDI de Bruker pour la caractérisation multimodale des tissus et inclut une évaluation des données alimentée par l'intelligence artificielle.
Selon le Dr Guillaume Mabilleau du Centre Hospitalier Universitaire Angers, la rapidité du microscope et la technologie QCL représentent une avancée significative pour la recherche clinique, notamment dans le diagnostic et le traitement des maladies osseuses. Le système prend également en charge l'inspection des comprimés pharmaceutiques et l'identification des particules avec échantillonnage automatisé, et inclut une interface Python pour la personnalisation.
Bruker (Nasdaq: BRKR) hat den LUMOS™ II ILIM eingeführt, ein auf quanten-kaskadierten Lasern (QCL) basierendes Infrarot-Imaging-Mikroskop, das für die pharmazeutische und biowissenschaftliche Forschung konzipiert wurde. Das Gerät verfügt über ein patentiertes Kohärenzreduktionsverfahren für artefaktfreies Infrarotlaser-Imagining sowohl im Übertragungs- als auch im Reflexionsmodus.
Das Mikroskop bietet ultradynamische IR-Imaging-Fähigkeiten über große Flächen mit verbesserter räumlicher Auflösung. Zu den Hauptmerkmalen gehören ein großes Sichtfeld, vollständige Automatisierung und die Möglichkeit, die chemische Komplexität in biologischen Geweben schnell zu bestimmen. Das System integriert sich mit Brukers MALDI-Imaging-Methoden zur multimodalen Gewebekarakterisierung und beinhaltet KI-gestützte Datenbewertung.
Laut Dr. Guillaume Mabilleau vom Centre Hospitalier Universitaire Angers stellt die Geschwindigkeit des Mikroskops und die QCL-Technologie einen bedeutenden Fortschritt für die klinische Forschung dar, insbesondere bei der Diagnose und Behandlung von Knochenerkrankungen. Das System unterstützt auch die Inspektion pharmazeutischer Tabletten und die Identifizierung von Partikeln mit automatisierter Probenahme und umfasst eine Python-Schnittstelle zur Anpassung.
- Introduction of new high-performance imaging technology expanding product portfolio
- Integration capabilities with existing Bruker MALDI Imaging systems
- AI-powered data evaluation features enhancing research capabilities
- Customization potential through Python interface
- None.
Insights
The LUMOS II ILIM represents a significant technological advancement in the analytical instrumentation market. The integration of quantum cascade laser (QCL) technology with automated microscopy addresses key bottlenecks in pharmaceutical research and clinical diagnostics. The system's ability to capture artifact-free IR images at high speed while maintaining superior resolution positions it uniquely in the $5.5 billion analytical instrument market.
The Python interface integration enables custom workflow development - a critical feature for research institutions and pharma companies looking to develop proprietary analytical methods. This flexibility, combined with AI-powered evaluation and MALDI imaging integration, creates a comprehensive analytical ecosystem that could drive recurring software and service revenues.
Think of this like upgrading from a basic digital camera to a professional DSLR with AI capabilities - it's not just about better pictures, but about opening new possibilities in image analysis and interpretation that weren't possible before.
The clinical implications of the LUMOS II ILIM are substantial for translational research. The system's enhanced capabilities in analyzing biological tissues at high throughput could accelerate drug development timelines and improve understanding of disease mechanisms. Dr. Mabilleau's endorsement regarding bone disease research is particularly noteworthy - rapid tissue analysis could lead to earlier disease detection and more precise treatment monitoring.
The multimodal imaging capability, combining infrared and MALDI imaging, provides researchers with complementary analytical techniques in a single platform. This is like having both X-ray and MRI capabilities in one machine - each technique reveals different aspects of the sample, providing a more complete understanding of complex biological systems.
From a market perspective, this launch strengthens Bruker's position in the high-end analytical instrumentation segment. The pharmaceutical industry's increasing focus on precision medicine and the growing demand for advanced analytical tools in life science research create a favorable market environment for this product. The automation features and high-throughput capabilities directly address the industry's need for increased efficiency and reduced time-to-market for new drugs.
For investors, this represents potential revenue growth in Bruker's Scientific Instruments segment, which typically carries higher margins. The recurring revenue opportunities through software updates, maintenance and consumables could provide steady cash flow streams. The product's positioning in both academic research and pharmaceutical industry applications diversifies its market potential and reduces dependency on any single customer segment.
Groundbreaking LUMOS II ILIM QCL-based IR microscope sets new standards in speed and resolution
LUMOS™ II ILIM quantum cascade laser (QCL) based infrared imaging microscope for pharma and life science research (Photo: Business Wire)
The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both transmission and reflection mode. With a very large field of view and complete automation, it allows for the rapid determination of chemical complexity in biological tissues.
Dr. Guillaume Mabilleau, Clinical Bone Pathologist at Centre Hospitalier Universitaire Angers in
Using AI-powered data evaluation, LUMOS II ILIM workflows allow for discoveries in life science, pharma and disease research. Integration with Bruker’s MALDI Imaging methods enable multimodal imaging to characterize tissues with enhanced analytical depth. The LUMOS II ILIM can also be used for rapid pharmaceutical tablet inspection and particle identification, including automated sampling. Users can harness a Python interface to adapt the LUMOS II ILIM to specific requirements and custom workflows. To learn more about LUMOS II ILIM, please visit: https://www.bruker.com/ILIM.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108014369/en/
Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Natalie Spahl
Head of Global Marketing
Bruker Optics Division
T: +49 173 9662425
E: Natalie.spahl@bruker.com
Source: Bruker Corporation
FAQ
What are the key features of Bruker's new LUMOS II ILIM microscope (BRKR)?
How does the LUMOS II ILIM benefit pharmaceutical research (BRKR)?
What clinical applications does Bruker's LUMOS II ILIM support (BRKR)?
How does LUMOS II ILIM integrate with existing Bruker technology (BRKR)?
